Source: FOX News
Summary
Researchers from the Universities of Cambridge and Southampton have developed a “universal vaccine” designed to protect against multiple Sarbeco coronaviruses, including SARS-CoV-2, using artificial intelligence. The vaccine has passed its first human clinical trial, proving safe and triggering an immune response in 39 healthy volunteers. The vaccine uses a “super-antigen” that contains common features of the virus group, including ones that haven’t emerged yet.
Our Reading
The advice sounds familiar.
A vaccine that could potentially provide broader protection against multiple coronaviruses has been developed, and it’s been tested in humans for the first time. The vaccine uses AI to design a “super-antigen” that contains common features of the virus group. The trial was safe and triggered an immune response in healthy volunteers. This new class of universal vaccines could potentially protect against related viruses that haven’t yet emerged.
It’s another example of how health guidance is constantly evolving, and what’s considered “future-proofed” today may need updating tomorrow.
Author: Evan Null
